Overview of Lipid Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Necrosis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Liver Physiology
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 6, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Veronika Zámbó1, Laura Simon-Szabó, Péter Szelényi
1Veronika Zámbó, Laura Simon-Szabó, Péter Szelényi, Éva Kereszturi, Gábor Bánhegyi, Miklós Csala, Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, H-1444 Budapest, Hungary.
Obesity drives non-alcoholic fatty liver disease (NAFLD). Saturated fatty acids, not triglycerides, cause liver injury by inducing oxidative stress and endoplasmic reticulum stress, leading to insulin resistance and apoptosis.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: